News Detail

Avalo prices $375 million follow-on offering at $17.75 per share

PUBT · 11h ago

Listen to the news

Avalo prices $375 million follow-on offering at $17.75 per share

Avalo Therapeutics priced an underwritten public offering of 19,730,000 common shares at USD 17.75 per share.
Offering also includes pre-funded warrants to buy 1,400,000 common shares at USD 17.749 per warrant, with a USD 0.001 exercise price.
Gross proceeds expected at about USD 375 million, excluding fees and assuming no exercise of underwriters’ option for up to 3,169,500 additional shares; closing expected May 7, 2026.
Net proceeds earmarked to advance clinical development of abdakibart through Phase 3 topline data release, with remainder for working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on May 05, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.